Taysha Gene Therapies Regains Full Global Rights to Lead Rett Syndrome Program TSHA-102

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best NASDAQ stocks under $5 to buy now. On October 16, Taysha Gene Therapies announced that it had regained full global rights to its lead program, TSHA-102, which is in clinical evaluation for the treatment of Rett syndrome. The 2022 Option Agreement between Taysha and Astellas has officially expired. The agreement granted Astellas an exclusive option to negotiate an exclusive license to TSHA-102 for Rett syndrome. Taysha now holds unencumbered right ...